Jan. 25 at 7:43 PM
$PCSA Imagine the sheer audacity of any management team who would so materially reward themselves personally while overseeing historical value destruction of nearly 99.9%. It speaks for itself.
Read the public filings, especially pay attention to the lawsuit of their primary drug 6422, which they appear to have now delayed interim results twice based on their previous public statements.
"Our general and administrative expenses for the nine months ended September 30, 2025 increased by approximately
$831,000 to
$4.6 million from
$3.8 million for the nine months ended September 30, 2024. This increase was due primarily to increases in salaries and other-payroll related costs of
$396,000, primarily due to salary increases to our C-suite executives; an increase of
$150,000 in investment management fees related to our recent cryptocurrency transaction; an increase in employee stock-based compensation of
$305,000"
